Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan

被引：0
|
作者：
Podder, Vivek
Ranjan, Tulika
Bardhan, Mainak
McCracken, Andrea
Hurmiz, Charlie
Ganiyani, Mohammad Arfat
Ahmad, Shahzaib
Mahtani, Reshma L.
Ahluwalia, Manmeet Singh
机构：
[1] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA
[2] Guardian Res Network, Spartanburg, SC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1036
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable and/or metastatic breast cancer: DESTINY-Breast-RESPOND
    O'Shaughnessy, Joyce
    Basho, Reva
    Lustberg, Maryam
    Lyman, Gary H.
    Prahladan, Manoj
    James, Gareth D.
    Varghese, Della
    Lujan, Flavia
    Tesch, Hans
    CANCER RESEARCH, 2024, 84 (09)
  • [22] Trastuzumab deruxtecan in the treatment of adult patients with HER2-positive breast cancer
    Kufel-Grabowska, Joanna
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (05): : 377 - 381
  • [23] CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses
    Jerusalem, G.
    Park, Y. H.
    Yamashita, T.
    Hurvitz, S. A.
    Chen, S.
    Cathcart, J.
    Lee, C.
    Perrin, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S63 - S64
  • [24] Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
    Shitara, Kohei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-Hee
    Sakai, Daisuke
    Chung, Hyun-Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Yamaguchi, Kensei
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25): : 2419 - 2430
  • [25] Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab
    P. S. Blanchette
    D. N. Desautels
    G. R. Pond
    J. M. S. Bartlett
    S. Nofech-Mozes
    M. J. Yaffe
    K. I. Pritchard
    Breast Cancer Research and Treatment, 2018, 170 : 169 - 177
  • [26] Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan
    Testa, Stefano
    Dickerson, James C.
    Telli, Melinda
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2023, 11
  • [27] Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab
    Blanchette, P. S.
    Desautels, D. N.
    Pond, G.
    Bartlett, J. M. S.
    Nofech-Mozes, S.
    Yaffe, M.
    Pritchard, K. I.
    CANCER RESEARCH, 2017, 77
  • [28] Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab
    Blanchette, P. S.
    Desautels, D. N.
    Pond, G. R.
    Bartlett, J. M. S.
    Nofech-Mozes, S.
    Yaffe, M. J.
    Pritchard, K. I.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (01) : 169 - 177
  • [29] Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
    Dhanushkodi, Manikandan
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 556 - 558
  • [30] Trastuzumab-Deruxtecan in the Therapy of HER2-positive Breast Cancer
    Schmale, Ine
    BREAST CARE, 2021, 16 (03)
12345